Day One Biopharmaceuticals Inc (DAWN) - News Archive

Showing 4 of 4 results.

Day One Biopharmaceuticals Secures Oversubscribed $175 Million Private Placement, While Maintaining Highest ROI Ranking in Healthcare Sector

BRISBANE, Calif., July 30, 2024 - Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has made significant strides in securing funding for its mission of developing and commercializing targeted therapies for individuals wit...

Jul 30, 2024 • Major Pharmaceutical Preparations Industry Management Announcement

Day One Acquires Exclusive License for Revolutionary ADC, MTX-13, Targeting PTK7 in Solid Tumors, Advancing Cancer Tr...

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on devel...

Jun 18, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Day One Biopharmaceuticals Achieves Record High Leverage Ratio Amidst $108 Million Priority Review Voucher Sale

On May 30, 2024, Day One Biopharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing targeted therapies, made a significant announcement. The company successfully sold its Priority...

May 30, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement

FDA Fast-Tracks Approval for OJEMDA, Day One's Novel Treatment for Leading Childhood Brain Tumor, MARKS Major Leap Forward in Pediatric Oncology

This latest regulatory green light marks just the latest affirmation of Day One s ongoing commitment to revolutionizing the treatment paradigm in pediatric oncology. With gliomas accounting for nearly half of all centra...

Apr 23, 2024 • Major Pharmaceutical Preparations Industry Clinical Study